It is also important to note that TP53 mutations are known to independently confer a poor prognosis in AML; hence, it is likely that the presence of this aberration would confound the interpretation of the outcomes of patients with AML with various RUNX1 lesions. The gene discussed is TP53; the disease is acute myeloid leukemia.